Dr Peter T Kennealey, MD | |
12605 E 16th Ave, Aurora, CO 80045-2545 | |
(720) 848-0000 | |
Not Available |
Full Name | Dr Peter T Kennealey |
---|---|
Gender | Male |
Speciality | General Surgery |
Experience | 24 Years |
Location | 12605 E 16th Ave, Aurora, Colorado |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073718680 | NPI | - | NPPES |
83502882 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | 48084 (Colorado) | Secondary |
204F00000X | Transplant Surgery | DR.0048084 (Colorado) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of Colorado Hospital Authority | Aurora, CO | Hospital |
Uchealth Highlands Ranch Hospital | Highlands ranch, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
University Physicians Incorporated | 3476465667 | 2657 |
University Physicians Incorporated | 3476465667 | 2657 |
News Archive
Newly published data confirm a non-invasive Respiratory Stress Response (RSR) can quickly and accurately measure the presence of significant coronary artery disease (sCAD), the leading cause of cardiovascular death worldwide. Patients in the study with sCAD had a lower RSR compared to patients without.
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Society of Clinical Oncology.
The U.S. Preventive Services Task Force and other organizations have recommended that women ages 65 and older be routinely screened for osteoporosis using bone mineral density (BMD) screening. However, how often women should be screened is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance.
› Verified 1 days ago
Entity Name | University Physicians Incorporated |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1962461889 PECOS PAC ID: 3476465667 Enrollment ID: O20031105000375 |
News Archive
Newly published data confirm a non-invasive Respiratory Stress Response (RSR) can quickly and accurately measure the presence of significant coronary artery disease (sCAD), the leading cause of cardiovascular death worldwide. Patients in the study with sCAD had a lower RSR compared to patients without.
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Society of Clinical Oncology.
The U.S. Preventive Services Task Force and other organizations have recommended that women ages 65 and older be routinely screened for osteoporosis using bone mineral density (BMD) screening. However, how often women should be screened is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance.
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Peter T Kennealey, MD Po Box 110429, Aurora, CO 80042-0429 Ph: (303) 493-7000 | Dr Peter T Kennealey, MD 12605 E 16th Ave, Aurora, CO 80045-2545 Ph: (720) 848-0000 |
News Archive
Newly published data confirm a non-invasive Respiratory Stress Response (RSR) can quickly and accurately measure the presence of significant coronary artery disease (sCAD), the leading cause of cardiovascular death worldwide. Patients in the study with sCAD had a lower RSR compared to patients without.
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Society of Clinical Oncology.
The U.S. Preventive Services Task Force and other organizations have recommended that women ages 65 and older be routinely screened for osteoporosis using bone mineral density (BMD) screening. However, how often women should be screened is a topic that remains controversial and undecided, with no definitive scientific evidence to provide guidance.
› Verified 1 days ago